99mTc-MIP-1404: Phase III started

Progenics began the open-label, North American Phase III proSPECT-AS trial to evaluate a single 20 mCi IV injection of 99mTc-MIP-1404 in about 450 patients with newly diagnosed low-grade prostate canc...